Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 341 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Choosing to act on cancer: Our Manifesto for Cancer Research and... April 20, 2023 FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... January 19, 2023 Combining existing drugs improves prostate cancer survival September 19, 2021 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 Load more HOT NEWS Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients... How Early Cancer Detection and Diagnosis Saved My Life Twice: A... A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... Survivor Guest Post: Living Breast-less
